Navigate peer-reviewed breakthroughs by pharmacological class, genetic target, circulating biomarker, or diagnostic modality. Select any clinical entity to inspect all linked studies.
Everyday Health & Science Hubs
Indexed Entities (24)
Drug / Therapy3 Peer-Reviewed Briefings
SGLT2 Inhibitors
Sodium-glucose cotransporter-2 inhibitors (dapagliflozin, empagliflozin) in cardiometabolic & renal care.
In heart transplant recipients, dapagliflozin, compared with placebo (inactive comparison treatment), improved the slope of the eGFR from 2 weeks to 12 months of treatment. Progressive kidney disease is common in heart transplant recipients due to calcineurin inhibitor exposure and pre-existing comorbidities.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
This Medical News article is an interview with Keisha Gibson, MD, MPH, cochair of the Kidney Week Education Committee and chief of pediatric nephrology at the University of North Carolina at Chapel Hill. Published in JAMA, these peer-reviewed nephrology findings provide quantitative evidence to inform clinical risk stratification, therapeutic decision-making, and follow-up trial design.
3/5 Observational
Evidence Meter · 3/5
Real-World Observation
Finds meaningful patterns in human health records or cohorts, though observational data cannot prove direct cause.
In a meta-analysis of randomized clinical trials, compared with control, SGLT2 inhibitor use was associated with small meaningful increases in hemoglobin and hematocrit levels. The clinical significance of these findings is unclear.
5/5 Gold Standard
Evidence Meter · 5/5
Gold-Standard Human Evidence
Backed by randomized controlled human trials or a formal meta-analysis pooling multiple clinical studies.
1 min read·JAMA·
Patient & Student Companion
Everyday Lab & Drug Translator
Instant plain-English guides for common blood tests and prescriptions—what normal ranges mean, what high/low values signal, and what to ask your clinician.
Lab Marker3-Month Blood Sugar
HbA1c
Measures the percentage of red blood cell hemoglobin coated with glucose over roughly 90 days.
Normal: below 5.7% · Prediabetes: 5.7%–6.4%
6.5% or higher on two tests diagnoses diabetes; very low values can occur alongside hypoglycemia or hemolytic anemia.
Ask your doctor: “Does my HbA1c match my daily fasting/post-meal glucose trends?”
Estimated glomerular filtration rate—how many milliliters of blood your kidneys filter every minute.
Healthy adult filter rate: 90+ mL/min/1.73m²
Values persistently below 60 for 3+ months (or elevated urine albumin) mark chronic kidney disease; single dips can simply reflect dehydration or NSAID use.
Ask your doctor: “Should we pair eGFR with a urine albumin-to-creatinine test (uACR)?”